Pharma IQ Members


Regina Au

Regina Au is a Strategic Marketing Consultant at BioMarketing Insight with over 20 years experience in the biotechnology, pharmaceutical, medical device, and diagnostic industries.  She helps companies evaluate their technology upfront by conducting an in-depth business due diligence to de-risk the product development process.  This ensures that the technology is the right product for the right market in meeting a critical unmet need and that the market potential for the product meets the business goals of the company.  She will translate these unmet needs into a product profile or specification.  Ms. Au then develops marketing strategies to ensure a successful product launch. 

Ms. Au also serves as an advisor for the Massachusetts Technology Transfer Center Platform Meetings with entrepreneurs and has served as a mentor in several organizations' mentoring programs.  Her expertise is in various therapeutic areas such as cardiology, interventional cardiology, infectious disease, immunology, surgery, gastroenterology, and pulmonology.

Prior to BioMarketing Insight she worked for companies such as Merck & Co., Genzyme Corp., NMT Medical, and Radi Medical Systems (now St. Jude Medical) in various positions of increasing responsibility in marketing and sales.  She had P&L responsibility in managing a number of multimillion dollar product lines and has experience in upstream and downstream marketing including strategic marketing, product development, market development, product launches, and product management.

Her background includes an MBA in Marketing from the University of Connecticut, a Microbiology degree from the University of Michigan and a Masters in International Management from Thunderbird School of Global Management.  

For more information go to:

While social media is taking the consumer world by storm, the medical industry has been a bit shy to fully embrace these channels because of regulatory requirements.
Why are IO therapies buzzing today? If we look back at the history of cancer treatment, the survival rate was measured in months, which according to oncologists was a lot back then, because the mortality rate in most cancers was 100%. Most traditional chemotherapies were not well tolerated, because they would kill both cancerous and healthy cells
In this Pharma IQ interview, Regina Au from BioMarketing Insight shares her insights on the current UDIs for medical devices landscape and the impact of the FDA’s final rule on UDIs on the medical device industry, both in the US and on a global scale. Au also reveals the 5 key business benefits for medical device manufacturers.
Regenerative medicine or man-made regeneration has been influenced and advanced the most with 3D printing technology. Scientists using stem cells and/or various forms of scaffolding have taken advantage of these technologies in such a short period of time and many different human parts have been reproduced: skin, ears, nose, eyes, bone, and
What does a leaky gut, and our gut microbiome, have to do with our immune system? Scientists are discovering that it has a lot to do with how well our immune system works.
In the medtech world, the boundaries between the semiconductor and medtech industries have already been blurred with chips, sensors and Micro-Electro-Mechanical Systems (MEMS). Today, the boundaries between high tech and medtech are starting to blur as well. Large high tech companies such as Google, Microsoft are trying to expand into the medtech